On the 25th June, Q2
released details of its completed Proof of Concept for tracking biological samples using distributed ledger technology (DLT). The project, with enterprise blockchain firm R3 and medical tech company HSBlox, involved a simulation of the entire process; collecting, transporting, testing, and storing the sample.
Q2, a joint venture of IQVIA and Quest Diagnostics to provide services to clinical trial labs, conducted the effort. Atlanta based HSBlox developed the patent-pending Digital Sample Manager for the project, which runs on R3’s Corda blockchain and Microsoft’s Azure.
The firms hope to streamline the handling of samples for clinical trials, where accuracy and efficiency are key. A mismatched label or contaminated sample could render the trial worthless, losing valuable research time and funding. Data must be checked and rechecked to ensure trust in the results, which are further reliant on sometimes “substandard” transportation logistics.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
